A total of 263 warfarin naive patients with indications to long-term anticoagulation were included in prospective multicenter study and randomized into Pharmacogenetics and Standard dosing groups. The loading warfarin dose in Pharmacogenetics group was calculated by Gage algorithm and corrected starting on day 5 of treatment according to INR. In Standard dosing group warfarin initial dose was 5 mg and starting on day 3 of treatment it was titrated according to INR. Pharmacogenetics dosing in comparison with prescription of starting dose of 5 mg decreased major bleedings (0 vs. 6, p = 0.031), time to target INR (11 [9-14] vs. 17 [15-24] days, p = 0.046), and frequency of INR fluctuations ≥4.0 (11% vs. 30.9%, p = 0.002). The advantages of the pharmacogenetics dosing were mainly achieved due to the patients with increased warfarin sensitivity.

中文翻译：

---

CYP2C9和VKORC1基因分型对俄罗斯患者长期使用华法林治疗的质量影响。

前瞻性多中心研究共纳入了263名华法林初治患者，这些患者具有长期抗凝的适应症，并随机分为药物遗传学组和标准剂量组。通过Gage算法计算药物遗传学组中的华法林负荷剂量，并根据INR从治疗的第5天开始对其进行校正。在标准给药组中，华法林的初始剂量为5 mg，从治疗的第3天开始，根据INR进行滴定。与开始剂量为5 mg的处方药相比，药物遗传学剂量减少了大出血（0 vs. 6，p = 0.031），达到目标INR的时间（11 [9-14] vs. 17 [15-24]天，p = 0.046 ），且INR波动频率≥4.0（11％比30.9％，p = 0.002）。药物遗传学剂量的优势主要是由于华法林敏感性增加的患者而实现的。